VANCOUVER, British Columbia, Dec. 8, 2011 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) will be hosting a Research and Development Day on Friday, December 16, 2011, starting at 8:30 a.m. EST / 5:30 a.m. PST in New York City. Bob Butchofsky, QLT's President and Chief Executive Officer, and Suzanne Cadden, Senior Vice President of Development, will be discussing the Company's clinical development and regulatory plans for the synthetic retinoid, QLT091001, for the treatment of Leber Congenital Amaurosis and Retinitis Pigmentosa, in addition to the Company's Punctal Plug Delivery System for the treatment of glaucoma. The meeting will include presentations by experts in the fields of inherited retinal diseases and glaucoma therapy, including: Dr. Alan Bird, Emeritus Professor at London University, Honorary consultant Moorfields Eye Hospital; Dr. Rob Koenekoop, Director, Ocular Genetics Lab at Montreal Children's Hospital, McGill University; Dr. Alan Robin, Associate Professor of Ophthalmology at Johns Hopkins, and Professor at University of Maryland; and Dr. Bob Williams, Senior Medical Advisor, QLT Inc., and founder of the Taustine Eye Center, Kentucky.
The Research and Development Day is for members of the professional investment community. For information on attending the event, please contact Christine Yang at cyang@troutgroup.com or Tricia Swanson at tswanson@troutgroup.com.
Interested parties may access the presentation slides and an audio recording after the event on QLT's website at www.qltinc.com.
About QLT
QLT is an ocular-focused company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases, developing our proprietary punctal plug delivery system, as well as U.S. marketing of the commercial product Visudyne® (which we co-developed with Novartis) for the treatment of wet age-related macular degeneration.
QLT's head office is based in Vancouver, Canada and the Company is publicly traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT). For more information about the Company's products and developments, please visit our web site at www.qltinc.com.
The QLT Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6933
Visudyne® is a registered trademark of Novartis AG.